Your browser doesn't support javascript.
loading
Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk.
Permuth, Jennifer B; Pirie, Ailith; Ann Chen, Y; Lin, Hui-Yi; Reid, Brett M; Chen, Zhihua; Monteiro, Alvaro; Dennis, Joe; Mendoza-Fandino, Gustavo; Anton-Culver, Hoda; Bandera, Elisa V; Bisogna, Maria; Brinton, Louise; Brooks-Wilson, Angela; Carney, Michael E; Chenevix-Trench, Georgia; Cook, Linda S; Cramer, Daniel W; Cunningham, Julie M; Cybulski, Cezary; D'Aloisio, Aimee A; Anne Doherty, Jennifer; Earp, Madalene; Edwards, Robert P; Fridley, Brooke L; Gayther, Simon A; Gentry-Maharaj, Aleksandra; Goodman, Marc T; Gronwald, Jacek; Hogdall, Estrid; Iversen, Edwin S; Jakubowska, Anna; Jensen, Allan; Karlan, Beth Y; Kelemen, Linda E; Kjaer, Suzanne K; Kraft, Peter; Le, Nhu D; Levine, Douglas A; Lissowska, Jolanta; Lubinski, Jan; Matsuo, Keitaro; Menon, Usha; Modugno, Rosemary; Moysich, Kirsten B; Nakanishi, Toru; Ness, Roberta B; Olson, Sara; Orlow, Irene; Pearce, Celeste L.
Affiliation
  • Permuth JB; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
  • Pirie A; Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
  • Ann Chen Y; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
  • Lin HY; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
  • Reid BM; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
  • Chen Z; Department of Biostatistics and Bioinformatics, Moffitt Cancer Center, Tampa, FL, USA.
  • Monteiro A; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
  • Dennis J; Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK.
  • Mendoza-Fandino G; Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
  • Anton-Culver H; Department of Epidemiology, Director of Genetic Epidemiology Research Institute, UCI School of Medicine, University of California Irvine, Irvine, CA, USA.
  • Bandera EV; Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Bisogna M; Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Brinton L; Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
  • Brooks-Wilson A; Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver BC, Canada.
  • Carney ME; Department of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada.
  • Chenevix-Trench G; Department of Obstetrics and Gynecology, John A Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, USA.
  • Cook LS; Genetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Queensland, Australia.
  • Cramer DW; Division of Epidemiology and Biostatistics, Department of Internal Medicine, University of New Mexico, Albuquerque, New Mexico, USA.
  • Cunningham JM; Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Cybulski C; Department of Laboratory of Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • D'Aloisio AA; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
  • Anne Doherty J; Social and Scientific Systems, Inc, Durham, NC, USA.
  • Earp M; Department of Epidemiology, Geisel School of Medicine, Dartmouth College, Hanover, NY, USA.
  • Edwards RP; Department of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.
  • Fridley BL; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Gayther SA; Ovarian Cancer Center of Excellence, Womens Cancer Research Program, Magee- Womens Research Institute & University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
  • Gentry-Maharaj A; Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA.
  • Goodman MT; Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA.
  • Gronwald J; Women's Cancer, Institute for Women's Health, University College London, London, UK.
  • Hogdall E; Cancer Prevention and Control, Samuel Oshin Comprehensive Cancer Institute, Cedars- Sinai Medical Center, Los Angeles, CA, USA.
  • Iversen ES; Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Jakubowska A; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
  • Jensen A; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark and Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Karlan BY; Department of Statistical Science, Duke University, Durham, NC, USA.
  • Kelemen LE; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
  • Kjaer SK; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Kraft P; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
  • Le ND; Department of Public Health Sciences, Medical University of South Carolina College of Medicine, Charleston, SC, USA.
  • Levine DA; Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
  • Lissowska J; Department of Gynaecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
  • Lubinski J; Program in Genetic Epidemiology and Statistical Genetics, Harvard TH Chan School of Public Health, Boston, MA, USA.
  • Matsuo K; Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada.
  • Menon U; Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Modugno R; Department of Cancer Epidemiology and Prevention, The Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland.
  • Moysich KB; International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.
  • Nakanishi T; Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Aichi, Japan.
  • Ness RB; Women's Cancer, Institute for Women's Health, University College London, London, UK.
  • Olson S; Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Orlow I; Ovarian Cancer Center of Excellence, Womens Cancer Research Program, Magee- Womens Research Institute & University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
  • Pearce CL; Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA.
Hum Mol Genet ; 25(16): 3600-3612, 2016 08 15.
Article in En | MEDLINE | ID: mdl-27378695
ABSTRACT
Rare and low frequency variants are not well covered in most germline genotyping arrays and are understudied in relation to epithelial ovarian cancer (EOC) risk. To address this gap, we used genotyping arrays targeting rarer protein-coding variation in 8,165 EOC cases and 11,619 controls from the international Ovarian Cancer Association Consortium (OCAC). Pooled association analyses were conducted at the variant and gene level for 98,543 variants directly genotyped through two exome genotyping projects. Only common variants that represent or are in strong linkage disequilibrium (LD) with previously-identified signals at established loci reached traditional thresholds for exome-wide significance (P < 5.0 × 10 - 7). One of the most significant signals (Pall histologies = 1.01 × 10 - 13;Pserous = 3.54 × 10 - 14) occurred at 3q25.31 for rs62273959, a missense variant mapping to the LEKR1 gene that is in LD (r2 = 0.90) with a previously identified 'best hit' (rs7651446) mapping to an intron of TIPARP. Suggestive associations (5.0 × 10 - 5 > P≥5.0 ×10 - 7) were detected for rare and low-frequency variants at 16 novel loci. Four rare missense variants were identified (ACTBL2 rs73757391 (5q11.2), BTD rs200337373 (3p25.1), KRT13 rs150321809 (17q21.2) and MC2R rs104894658 (18p11.21)), but only MC2R rs104894668 had a large effect size (OR = 9.66). Genes most strongly associated with EOC risk included ACTBL2 (PAML = 3.23 × 10 - 5; PSKAT-o = 9.23 × 10 - 4) and KRT13 (PAML = 1.67 × 10 - 4; PSKAT-o = 1.07 × 10 - 5), reaffirming variant-level analysis. In summary, this large study identified several rare and low-frequency variants and genes that may contribute to EOC susceptibility, albeit with possible small effects. Future studies that integrate epidemiology, sequencing, and functional assays are needed to further unravel the unexplained heritability and biology of this disease.
Subject(s)

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Actins / Neoplasms, Glandular and Epithelial / Biotinidase / Receptor, Melanocortin, Type 2 / Keratin-13 Type of study: Etiology_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Hum Mol Genet Journal subject: BIOLOGIA MOLECULAR / GENETICA MEDICA Year: 2016 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Actins / Neoplasms, Glandular and Epithelial / Biotinidase / Receptor, Melanocortin, Type 2 / Keratin-13 Type of study: Etiology_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Hum Mol Genet Journal subject: BIOLOGIA MOLECULAR / GENETICA MEDICA Year: 2016 Type: Article Affiliation country: United States